Trials / Completed
CompletedNCT01627262
Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study
Double-blind, Randomised, Placebo-controlled, Parallel-group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Pellets vs. Placebo in Diverticular Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 123 (actual)
- Sponsor
- Dr. Falk Pharma GmbH · Industry
- Sex
- All
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether mesalamine is effective in the treatment of uncomplicated diverticular disease by reducing the pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mesalamine | 3x1000mg mesalamine granules per day |
| DRUG | Placebo | 3x1000mg placebo granules per day |
Timeline
- Start date
- 2002-05-01
- Primary completion
- 2004-08-01
- Completion
- 2006-04-01
- First posted
- 2012-06-25
- Last updated
- 2016-01-21
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01627262. Inclusion in this directory is not an endorsement.